NGR006: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Colorectal Cancer (CRC), Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan Based Regimens.

Trial Profile

NGR006: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Colorectal Cancer (CRC), Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan Based Regimens.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2014

At a glance

  • Drugs NGR-TNF (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors MolMed
  • Most Recent Events

    • 03 Jun 2013 Data were presented at the 49th ASCO annual meeting, according to a MolMed media release.
    • 22 Sep 2010 Status changed from active, no longer recruiting to completed, according to a MolMed media release.
    • 25 Aug 2010 Positive results of this study have been published in the European Journal of Cancer (doi:10.1016/j.ejca.2010.07.012; published online ahead of print), as reported in a MolMed media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top